NAV

Lurtotecan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Lurtotecan
DrugBank Accession Number
DB12222
Background

Lurtotecan is under investigation in clinical trial NCT00022594 (Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 518.57
Monoisotopic: 518.216534702
Chemical Formula
C28H30N4O6
Synonyms
  • Lurtotecan
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmbroxolThe risk or severity of methemoglobinemia can be increased when Lurtotecan is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Lurtotecan is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Lurtotecan is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Lurtotecan is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Lurtotecan is combined with Bupivacaine.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring).
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Camptothecins
Sub Class
Not Available
Direct Parent
Camptothecins
Alternative Parents
Quinolines and derivatives / Pyranopyridines / Benzo-1,4-dioxanes / Alkyl aryl ethers / Pyridinones / Aralkylamines / N-methylpiperazines / Para dioxins / Benzenoids / Tertiary alcohols
show 13 more
Substituents
1,4-diazinane / Alcohol / Alkyl aryl ether / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Benzo-1,4-dioxane
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
4J1L80T08I
CAS number
149882-10-0
InChI Key
RVFGKBWWUQOIOU-NDEPHWFRSA-N
InChI
InChI=1S/C28H30N4O6/c1-3-28(35)20-11-22-25-18(14-32(22)26(33)19(20)15-38-27(28)34)17(13-31-6-4-30(2)5-7-31)16-10-23-24(12-21(16)29-25)37-9-8-36-23/h10-12,35H,3-9,13-15H2,1-2H3/t28-/m0/s1
IUPAC Name
(18S)-18-ethyl-18-hydroxy-2-[(4-methylpiperazin-1-yl)methyl]-6,9,20-trioxa-13,24-diazahexacyclo[12.11.0.0^{3,12}.0^{5,10}.0^{15,24}.0^{17,22}]pentacosa-1(14),2,4,10,12,15,17(22)-heptaene-19,23-dione
SMILES
CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=C4OCCOC4=CC1=C3CN1CCN(C)CC1)C2=O

References

General References
Not Available
PubChem Compound
60956
PubChem Substance
347828501
ChemSpider
54919
BindingDB
50036130
ChEMBL
CHEMBL305666
ZINC
ZINC000022010625
Wikipedia
Lurtotecan

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
2CompletedTreatmentFallopian Tube Cancer / Ovarian Cancer / Peritoneal Cancer1
2CompletedTreatmentHead And Neck Cancer1
2CompletedTreatmentOvarian Neoplasms1
2CompletedTreatmentSmall Cell Carcinoma / Small Cell Lung Cancer (SCLC)1
1CompletedTreatmentHead And Neck Cancer / Lung Cancer / Ovarian Cancer / Unspecified Adult Solid Tumor, Protocol Specific1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.713 mg/mLALOGPS
logP1.66ALOGPS
logP0.52Chemaxon
logS-2.9ALOGPS
pKa (Strongest Acidic)11.71Chemaxon
pKa (Strongest Basic)7.86Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area104.67 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity140.04 m3·mol-1Chemaxon
Polarizability56.18 Å3Chemaxon
Number of Rings7Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0000090000-d99922f288af6b431be0
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-01b9-0000900000-9242e22a6869e5d63bbe
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0uxr-0101890000-3672637e75b87c0c14e6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0000900000-0c7e095ef6f7ef9f6819
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-1401920000-a614a69dd120294d335d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0102920000-ab3e2e34d5ebfacb2198
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-248.5888049
predicted
DarkChem Lite v0.1.0
[M-H]-210.19907
predicted
DeepCCS 1.0 (2019)
[M+H]+249.1041049
predicted
DarkChem Lite v0.1.0
[M+H]+212.59464
predicted
DeepCCS 1.0 (2019)
[M+Na]+248.5756049
predicted
DarkChem Lite v0.1.0
[M+Na]+218.50716
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 21:39 / Updated at February 21, 2021 18:53